Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archived Events
Date Event Details
Jun 17, 2017
MacroGenics Presentation at the Annual European Congress of Rheumatology (EULAR 2016)
Jun 5, 2017
9:00 AM ET
Trials-in-Progress Poster Presentation at ASCO Annual Meeting 2017
May 16, 2017
4:00 PM ET
MacroGenics Presentation at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 3, 2017
4:30 PM ET
MacroGenics, Inc. First Quarter 2017 Financial Results Conference Call
May 3, 2017
1:30 PM ET
MacroGenics Presentation at the Deutsche Bank 42nd Annual Health Care Conference
Apr 2–4, 2017
1:00 PM ET
Presentation of eight posters at 2017 AACR Annual Meeting
  • Preclinical Development of a Duocarmycin-Based ADC Targeting B7-H3 for Solid Cancer
  • Target Validation, Antibody Discovery and Preclinical Data Supporting ADAM9 as ADC
  • Novel ADC Targeting ADAM9-expressing Solid Tumors Demonstrate Potent Preclin. Activity 
  • Tumor-Antigen Expression-Dependent Activ. of CD137 Costim. Pathway by DART Proteins 
  • Co-targeting PD-1 and CTLA-4 Inhibitory Pathways with DART and TRIDENT Molecules 
  • Potent Antitumor Activity of Duvortuxizumab (CD19 x CD3 DART) in Lymphoma Models 
  • Quant. Prediction of Human PK for Duvortuxizumab: a Translational PK Model. Approach 
  • 5T4 x CD3 DART Molecule w/ Extended Half-life for T-cell Immunotherapy of Cancers 
Feb 28, 2017
4:30 PM ET
MacroGenics, Inc. Fourth Quarter and Full Year 2016 Financial Results Conference Call
Jan 20, 2017
Margetuximab TIP Poster Presentation at 2017 ASCO Gastrointestinal Cancers Symposium
Dec 13, 2016
8:30 AM ET
MacroGenics, Inc. R&D Day 2016
Dec 7, 2016
Margetuximab TIP Poster Presentation at San Antonio Breast Cancer Symposium 2016
Jun 10, 2016
5:40 AM ET
MacroGenics Presentation at the Annual European Congress of Rheumatology (EULAR 2016)
Jun 5, 2016
9:00 AM ET
Trials-in-Progress Poster Presentation at ASCO Annual Meeting 2016
Apr 17–19, 2016
2:00 PM ET
Five Posters Presented at 2016 American Association for Cancer Research (AACR) Annual Meeting
Mar 7, 2016
Preclinical Data Presented at Keystone Symposia's Antibodies as Drugs (X2) Conference: MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors
Nov 7, 2015
12:00 PM ET
Data presented at SITC Annual Meeting 2015: Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3
May 30, 2015
8:00 AM - 11:30 AM CT
Data Presented at ASCO Annual Meeting 2015:
Updated findings of a first-in-human phase 1 study of margetuximab, an Fc-optimized chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

Location: S Hall A
Poster Board Number: 11
Abstract Number: 523
Presented by: Howard A. Burris, M.D.

Apr 20, 2015
1:00 PM - 5:00 PM ET
Preclincal Data Presented at AACR Annual Meeting 2015:
DART® molecules with enhanced DR5 agonistic activity for improved cancer cell cytotoxicity

Location: Poster section 25
Poster Board Number: 6
Abstract Number: 2464
Presented by: MacroGenics, Inc

Dec 6, 2014
5:30 PM ET
Preclinical Data Presented at ASH 2014 Annual Meeting:
MGD011, a Humanized CD19 x CD3 DART® Protein with Enhanced Pharmacokinetic Properties, Demonstrates Potent T-cell Mediated Anti-Tumor Activity in Preclinical Models and Durable B-cell Depletion in Cynomolgus Monkeys Following Once-a-Week

Presenter: Liqin Liu, Ph.D., Senior Scientist at MacroGenics
Session Name: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
Presentation Date and Time: Saturday, December 6, 2014; 5:30 PM - 7:30 PM PT
Location: West Building, Level 1 (Moscone Center)
Abstract Number: 1775

Nov 19, 2014
Poster presentation at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain:
Preclinical Activity and Safety of MGD006/S80880, a CD123 x CD3 Bispecific DART® Molecule for the Treatment of Hematological Malignancies
  •          View MGD006 EORTC-NCI-AACR Poster
Nov 6, 2014
10:00 AM ET
Trials-in-progress posters presented at the 29th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD:
  • MGD006  - A Phase 1 trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
  • MGD007  - A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Relapsed/Refractory Metastatic Colorectal Carcinoma
May 5, 2014
2:30 PM ET
MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
Apr 6, 2014
4:00 PM ET
AACR Poster Presentation: Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer
Location: 1:00-5:00pm PDT in Hall A-E, poster section 28, poster number 26
Dec 9, 2013
11:45 AM CT
ASH Oral Presentation:
Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs)
Speaker: Muneera H. Al-Hussaini, M.D., an investigator from the Division of Hematology & Oncology, Washington University School of Medicine in St. Louis
Location: La Nouvelle Ballroom C (Ernest N. Morial Convention Center)

The team investigated the ability of a DART constructed from an antibody to CD123 (7G3) and a MacroGenics' proprietary CD3 antibody, MGD006, to redirect T cells against CD123+ AML blasts. 

Click here for more information.

= add file to Briefcase

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close